Open an account

NeuroOne Medical Technologies

NMTC · NASDAQ

$0.9838−$0.0162 (−1.62%)TodayMarket closed ·
Prev close $1.00

About NMTC

NeuroOne Medical Technologies Corp is a US-based company operating in Health Care Equipment & Supplies industry. The company is headquartered in Eden Prairie, Minnesota and currently employs 18 full-time employees. The company went IPO on 2012-11-09. NeuroOne Medical Technologies Corporation is a medical technology company. The company is developing and commercializing minimally invasive and hi-definition solutions for EEG recording, brain stimulation and ablation solutions for patients suffering from epilepsy, Parkinson’s disease, dystonia, essential tremors, chronic pain due to failed back surgeries and other related neurological disorders. The company may also pursue applications for other areas such as depression, mood disorders, incontinence and artificial intelligence. Its products include Evo cortical electrode technology for recording, monitoring, and stimulating brain tissue for up to 30 days; Evo sEEG electrode technology for temporary (less than 30 days) use with recording, monitoring, and stimulation equipment for the recording, monitoring, and stimulation of electrical signals at the subsurface level of the brain, and OneRF ablation system for creation of radiofrequency lesions in nervous tissue for functional neurosurgical procedures.

Employees
18
Headquarters
Eden Prairie, Minnesota
Listed
Nov 9, 2012
Sector
Health Care
Industry
Health Care Equipment & Supplies
Website
nmtc1.com

NMTC key statistics

Market cap
8.96M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
173.93K
Volume
35.14K
Open price
$1.03
High today
$1.03
Low today
$0.9649
52 Week high
$6.12
52 Week low
$0.95

NeuroOne Medical Technologies (NMTC) at a glance

As of Oct 20, 2026, NeuroOne Medical Technologies (NMTC) shares are priced at $0.9838, giving the company a market cap of 8.96M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $0.9649 and $1.03. The current price is 2.0% above the day's low and 4.5% below its high.

Volume so far is 35.14K shares, below the average of 173.93K shares a day.

Over the past year NeuroOne Medical Technologies has ranged from $0.95 to $6.12, and now sits 1% of the way up that range.

NeuroOne Medical Technologies met or beat analyst EPS estimates in 5 of the last 8 quarters. In Q3 FY26 it reported -$0.23 per share against an estimate of -$0.221.

The average analyst price target is $7.41, 653.4% above the current price, from 3 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

100%of 3 analyst ratings say Buy
  • Buy100.0%
  • Hold0.0%
  • Sell0.0%
Price target · 5 analystsAvg $7.41
Low
$5.05
Now
$0.9838
High
$9.24

NMTC earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 5 of the last 8 quarters, by 50.4% on average.

  1. Q4 FY24: reported -$0.11 per share against an estimate of -$0.0816
  2. Q1 FY25: reported $0.06 per share against an estimate of -$0.102
  3. Q2 FY25: reported -$0.07 per share against an estimate of -$0.0918
  4. Q3 FY25: reported -$0.18 per share against an estimate of -$0.306
  5. Q4 FY25: reported -$0.24 per share against an estimate of -$0.2448
  6. Q1 FY26: reported -$0.18 per share against an estimate of -$0.2448
  7. Q2 FY26: reported -$0.25 per share against an estimate of -$0.2312
  8. Q3 FY26: reported -$0.23 per share against an estimate of -$0.221

NMTC news

  • 12 Health Care Stocks Moving In Tuesday's After-Market Session

  • NeuroOne Medical Tech Q2 2026 Earnings Call Transcript

  • Press releasePRNewswire

    Next-Generation Platforms Scale Across Energy, Wellness, and Smokeless Consumer Segments

  • 12 Health Care Stocks Moving In Tuesday's Intraday Session

  • 12 Health Care Stocks Moving In Monday's After-Market Session

  • Press releaseGlobe Newswire

    NeuroOne® Patient Surpasses One Year Milestone of Seizure Freedom Following Treatment with OneRF® Ablation System

  • Press releaseGlobe Newswire

    NeuroOne® Reports Second Quarter Fiscal Year 2025 Financial Results; Gross Margin Improves Significantly YoY to 55.6%

  • Press releaseGlobe Newswire

    NeuroOne® Completes FDA Submission for the OneRF® Trigeminal Nerve Ablation System to Treat Facial Pain

Similar companies

Companies in the same industry as NeuroOne Medical Technologies

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.